Learn how to master CD138 cell enrichment for FISH, with tips on improving probe penetration, eliminating residual antibodies and more.
Read articleLearn how to master CD138 cell enrichment for FISH, with tips on improving probe penetration, eliminating residual antibodies and more.
ReadNGS has emerged as a promising approach to detect measurable residual disease (MRD) in AML. In this blog we provide an overview of conventional methods currently employed such as Flow Cytometry, and discuss why NGS is a valuable addition to the technologies used for MRD assessment.
ReadDiscover how next-generation sequencing is reshaping CLL prognosis, streamlining the process and offering more comprehensive insights than ever before.
ReadGain an understanding of the relationship between sequencing depth and Variant Allele Frequency (VAF) sensitivity, which plays a significant role in accurately detecting genetic variants, especially in Measurable Residual Disease (MRD) detection.
ReadLearn how to combat high background fluorescence in your FISH assays with inside tips on sample preparation, hybridisation conditions and more.
ReadAt OGT we are proud of the collaborations we have with labs all over the world. In this blog discover how Norah O. Akinola, Professor of Haematology at the Obafemi Awolowo University in Nigeria, worked with OGT experts to establish a FISH laboratory by upgrading their existing cytogenetics facility.
ReadWe explore the guidelines and the different methods for fusion event detection, including the potential of RNA-based NGS to help pave the way for personalised therapies and improved patient outcomes.
ReadIf you currently rely upon IVDD probes and are unsure about when or how to switch to a new IVDR platform, we’re here to help you. Find out why you should move to IVDR...
ReadToday we celebrate International Day of Women and Girls in Science. Our OGT family includes many women having successful STEM careers. Take a look at some of their stories across various roles in the OGT organisation...
ReadIn the second part of our latest blog series - “Old biomarkers, new tricks" - we highlight the ongoing efforts to bring BCL-2 inhibitors to the forefront in t(11:14) translocation cases of multiple myeloma, and how FISH probes can support clinical investigations.
ReadDidn’t get a chance to talk to us at ASH 2023? Read the first part of our latest blog series, which describes the potential of menin inhibitors for acute leukaemia, including the use of IVDR approved FISH probes in clinical trials.
ReadIn March 2023, we became the very first manufacturer of FISH probes to be granted IVDR certification. In our latest blog we speak with Steve Chatters, Executive Vice President of Regulatory, Medical and Quality Affairs, about OGT's long-standing expertise in healthcare regulation, and the journey towards IVDR certification.
Read
Visit USA site
Visit Canada site
